达托霉素剂量对万古霉素耐药粪肠球菌菌血症结局的影响
该前瞻性观察性队列研究纳入2010-2015年112例接受达托霉素≥6 mg/kg治疗的万古霉素耐药粪肠球菌血流感染患者,发现达托霉素剂量≥9 mg/kg与较低死亡率相关,且未增加肌酸激酶升高风险。
要点
- 达托霉素≥9 mg/kg组死亡率20%,低于<7 mg/kg组的50%和7-9 mg/kg组的33.3%。
- 多因素分析显示≥9 mg/kg相比<7 mg/kg的调整OR为10.57(95%CI 2.25-49.62)。
- 达托霉素MIC与死亡率无显著差异,剂量与肌酸激酶升高无关联。
核心结论
- 较高剂量达托霉素(≥9 mg/kg)与万古霉素耐药粪肠球菌血流感染患者较低死亡率相关。
研究设计与样本
- 前瞻性观察性队列研究,2010-2015年纳入112例接受达托霉素≥6 mg/kg治疗的万古霉素耐药粪肠球菌血流感染患者。
主要发现
- 总体死亡率为40/112(35.7%)。
- 未调整死亡率:<7 mg/kg组18/36(50.0%),7-9 mg/kg组17/51(33.3%),≥9 mg/kg组5/25(20%)(P = .05)。
- ≥9 mg/kg相比<7 mg/kg的调整OR为10.57(95%CI 2.25-49.62;P=.003),相比7-9 mg/kg的调整OR为5.01(95%CI 1.14-21.98;P=.03)。
- 达托霉素MIC为4 mg/L者78例(69.6%),≤2 mg/L者34例(30.4%),MIC与死亡率无显著差异。
- 达托霉素剂量与肌酸激酶升高无关联。
临床怎么用
- 对于万古霉素耐药粪肠球菌血流感染,可考虑使用较高剂量达托霉素(≥9 mg/kg)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment options for vancomycin-resistant enterococci (VRE) bloodstream infection (BSI) are limited. Daptomycin, although not currently approved for this indication, is frequently used for the treatment of VRE-BSI. Its optimal dose still needs to be determined. METHODS: We conducted a prospective, observational, cohort study during 2010-2015. We included patients who received a daptomycin dose of ≥6 mg/kg for the treatment of VRE-BSI caused by daptomycin-susceptible VRE. The primary endpoint was 14-day mortality, and multivariable logistic regression was performed for outcome analysis. RESULTS: We included 112 patients treated with daptomycin for VRE-BSI and with evaluable clinical outcomes. The daptomycin minimum inhibitory concentration (MIC) was 4 mg/L in 78 (69.6%) and ≤2 mg/L in 34 (30.4%) isolates. The overall mortality was 40/112 (35.7%). The unadjusted mortality was 18/36 (50.0%) for a daptomycin dose of <7 mg/kg, 17/51 (33.3%) for a dose of 7-9 mg/kg, and 5/25 (20%) for a dose of ≥9 mg/kg (P = .05). The best outcomes were associated with a daptomycin dose of ≥9 mg/kg compared to doses of <7 mg/kg (adjusted odds ratio [aOR], 10.57; 95% confidence interval [CI], 2.25-49.62; P=.003) and 7-9 mg/kg (aOR, 5.01; 95% CI, 1.14-21.98; P=.03). There was no significant difference in mortality with respect to the daptomycin MIC. There was no association between daptomycin dose and elevated creatinine kinase. CONCLUSION: Higher daptomycin doses (≥9 mg/kg) were associated with lower mortality in patients with VRE-BSI. Our results suggest that higher daptomycin doses need to be considered for VRE-BSI treatment.
引用
- Chuang YC, Lin HY, Chen PY, et al. Effect of Daptomycin Dose on the Outcome of Vancomycin-Resistant, Daptomycin-Susceptible Enterococcus faecium Bacteremia. Clin Infect Dis. 2017. PMID: 28329222. doi:10.1093/cid/cix024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。